The association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) patients receiving cyclin-dependent kinase 4/6 inhibitor (CDKI).
Herein, RBC balanced immuno-inflammatory (RBC-IMM) score was developed and capable of predicting progression-free survival (PFS) events (
